Nasal Spray vs Injection: Peptide Delivery Routes Compared

Delivery route is one of the most underappreciated variables in any peptide protocol, because it largely determines how much of the dose actually reaches your bloodstream. Most peptides are injected for a simple reason: the digestive tract breaks them down, so swallowing them does not work. A small handful, mainly the nootropic peptides semax and selank, are designed for nasal delivery instead. None of this changes the underlying regulatory reality, which is that most of these peptides are not FDA-approved.

Why Route Matters So Much for Peptides

Peptides are short chains of amino acids, the same building blocks that make up dietary protein. That is the entire problem. Your digestive system is built to break protein down into its components, so a peptide that travels through the stomach and gut is mostly destroyed before it can be absorbed intact and do anything.

The technical term for "how much of an administered dose reaches systemic circulation in active form" is bioavailability. For peptides taken orally, bioavailability is usually very low. That single fact is why injection, which bypasses the gut completely, is the default delivery route for most peptide protocols.

The choice, then, is rarely "pill versus shot." For most peptides it is "injection," and for a small subset it is "injection versus nasal spray."

Subcutaneous Injection: The Default

Subcutaneous (SubQ) injection delivers the peptide into the fatty tissue just under the skin, using a short, fine needle. It is the most common route for peptides because it offers high, relatively predictable bioavailability and slow, steady absorption.

Most research peptides, the GH secretagogues, the healing peptides, and others, are administered this way. The tradeoff is obvious: it involves needles, reconstitution, and sterile technique. For the practical side of preparing an injectable peptide, see how to reconstitute peptides, and for the site and technique questions, peptide injection sites: SubQ vs IM.

Some protocols use intramuscular (IM) injection instead, which delivers into muscle for faster absorption. For most peptides SubQ is sufficient, and the SubQ-versus-IM decision is a separate question covered in that sites guide.

Nasal Spray: Convenience for a Narrow Set

Intranasal delivery sprays the peptide onto the nasal lining (mucosa), where some of it absorbs across that tissue. The appeal is real: no needles, no reconstitution math, and for some compounds a more direct path toward the brain, which is why the nasal route is associated with the nootropic and anxiolytic peptides.

The peptides most commonly used this way are semax and selank, both developed in Russia and both typically used as nasal sprays. Their small molecular size helps them cross the nasal mucosa, and the cognitive and anxiety-related goals fit a route that can reach the central nervous system.

The tradeoff is bioavailability and consistency. Absorption across the nasal lining is generally lower and more variable than injection, affected by technique, congestion, and how much simply drips away or is swallowed. Nasal sprays prioritize convenience over maximal, predictable absorption. Chronic intranasal use also has not been well studied for long-term effects on the nasal mucosa itself.

Crucially, semax and selank are not FDA-approved in the US, and most of their clinical evidence is regional (primarily Russian) rather than validated in large Western trials. The nasal route does not change that.

Oral: Mostly a Dead End

Oral peptide delivery is the route most people wish worked, and for most peptides it does not, for the gut-breakdown reasons above. There are narrow exceptions, where specialized formulation technology or an unusually stable peptide allows some oral activity, but for the peptides discussed across this cluster, oral delivery is generally not a reliable option.

This is worth stating plainly because "oral peptide" products are marketed, and for most molecules the absorbed active dose is negligible.

There are research efforts to make oral peptide delivery work, using protective coatings, absorption enhancers, or co-formulated agents, and a small number of approved peptide drugs use such technology. But those are purpose-built pharmaceutical products, not something that applies to generic research peptides sold as powder. For the peptides in this cluster, "can I just take it orally" almost always has the same answer: not effectively.

Route Comparison at a Glance

The table below compares the three routes on the dimensions that actually matter when a provider is choosing. "Bioavailability" here is directional, since exact figures vary by specific peptide and formulation.

Factor	Subcutaneous Injection	Nasal Spray	Oral
Typical bioavailability	High and relatively predictable	Lower and more variable	Very low for most peptides
Needles required	Yes	No	No
Reconstitution math	Usually yes	Sometimes (pre-mixed sprays exist)	Generally no
Peptides that fit	Most (GH secretagogues, healing peptides, many others)	Small nootropic/anxiolytic peptides (semax, selank)	Very few, narrow exceptions
Main advantage	Maximal, consistent absorption	Convenience, needle-free, CNS-directed	Convenience (if it worked)
Main limitation	Needles, technique, supplies	Lower/variable absorption	Gut breakdown destroys most peptides
Tracking implication	Log dose, site, vial concentration	Log dose and sprays per session	Rarely relevant

This is general education, not a recommendation to use any specific peptide or route. Most of the substances in the nasal and injectable columns are not FDA-approved, and route choice belongs with a licensed provider.

The Practical Tradeoffs Beyond Bioavailability

Bioavailability gets the headline, but the day-to-day tradeoffs are what people actually live with, and they cut in different directions.

Adherence and aversion. For someone with genuine needle anxiety, a nasal spray they will actually use beats an injection they keep skipping. Adherence is part of effectiveness; the most bioavailable route does nothing if it sits unused in a drawer.

Dose precision. Injection wins here. A volume drawn to a unit mark on a syringe is a precise, repeatable dose. "Two sprays per nostril" is inherently fuzzier, because how much absorbs depends on technique, head position, congestion, and how much drips out or is swallowed.

Consistency over time. Injected protocols tend to produce more reproducible exposure session to session. Nasal absorption can swing with a head cold, allergies, or simply inconsistent spray technique, which makes it harder to attribute any effect, or lack of one, to the peptide itself.

Supplies and complexity. Nasal sprays are often supplied pre-mixed and need no reconstitution math, which lowers the barrier to entry. Injectables require syringes, a diluent, sterile technique, and the concentration math covered in our reconstitution guide. That complexity is a real cost, even if it buys better absorption.

None of these tradeoffs has a universal winner. They are exactly the kind of context a clinician weighs against the specific peptide and your situation.

A Note on Local vs Systemic Goals

One more wrinkle: some injection conventions are about reaching a specific tissue, not just maximizing systemic levels. With certain healing peptides, community practice favors injecting near the area of interest on the theory of a local effect, a convention with limited hard evidence, discussed in the peptide injection sites guide. Nasal delivery, by contrast, is chosen partly to reach the central nervous system. The point is that "best route" depends on where you are trying to get the peptide, not just how much of it reaches the blood.

How Route Changes the Way You Track

A point that gets overlooked: the delivery route changes what "a dose" even means in your log. An injectable dose is a volume drawn from a vial at a known concentration, so the meaningful record is milligrams or micrograms, the reconstituted concentration, and the site. A nasal dose is typically a number of sprays per nostril, where the actual absorbed amount is inherently fuzzier.

That difference matters most when someone runs a mixed-delivery protocol, for example a nasal nootropic alongside an injectable recovery peptide. Keeping those in one coherent record, with the right unit for each route, is exactly the kind of thing that falls apart in a notes app.

Myo, an iOS app by PixelPort LLC, logs the route, timing, dose, and site for each entry, so a mixed nasal-and-injectable routine stays in a single timeline rather than scattered across formats. For injectables, you can pull the concentration from the reconstitution calculator and save it to the vial so every dose reads off correct math. Myo is a tracking and education tool only; it does not source, prescribe, or recommend any substance.

Understanding how levels rise and fall over a dosing interval is part of using any route well; the GLP-1 dose week and PK curve article explains that pharmacokinetic thinking in a context with much stronger evidence, and the same logic applies to how you time and track peptide doses.

The Bottom Line

Route is a pharmacology decision, not a style choice. Injection maximizes and stabilizes absorption and suits most peptides; nasal spray buys convenience for a narrow set, mainly semax and selank, at the cost of some absorption; oral delivery mostly does not work. None of these routes changes the fact that most of these peptides are unapproved and that the decision belongs with a licensed clinician.

References

Swolverine: Semax and Selank Nootropic Peptides Compared Overview of semax and selank, including their typical intranasal administration and regional evidence base. https://swolverine.com/blogs/blog/semax-vs-selank-nootropic-peptides-compared

FDA: Safely Using Sharps (Needles and Syringes) FDA guidance on injection supplies and safe handling, relevant to the subcutaneous route. https://www.fda.gov/medical-devices/consumer-products/safely-using-sharps-needles-and-syringes-home-work-and-travel

FDA: Compounding and Unapproved Drugs FDA resources on the regulatory status of compounded and unapproved peptide products. Verify current status at FDA.gov. https://www.fda.gov/drugs/human-drug-compounding